AR045700A1 - Derivados de combretastatina que presentan actividad citotoxica - Google Patents

Derivados de combretastatina que presentan actividad citotoxica

Info

Publication number
AR045700A1
AR045700A1 ARP040102518A ARP040102518A AR045700A1 AR 045700 A1 AR045700 A1 AR 045700A1 AR P040102518 A ARP040102518 A AR P040102518A AR P040102518 A ARP040102518 A AR P040102518A AR 045700 A1 AR045700 A1 AR 045700A1
Authority
AR
Argentina
Prior art keywords
hydrogen
phenyl
methoxy
trimethoxy
double
Prior art date
Application number
ARP040102518A
Other languages
English (en)
Inventor
Daniele Simoni
Romeo Romagnoli
Giuseppe Giannini
Domenico Alloati
Claudio Pisano
Original Assignee
Sigma Tau Ind Farmaceuti
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sigma Tau Ind Farmaceuti filed Critical Sigma Tau Ind Farmaceuti
Publication of AR045700A1 publication Critical patent/AR045700A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D261/12—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C43/00—Ethers; Compounds having groups, groups or groups
    • C07C43/02—Ethers
    • C07C43/20—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring
    • C07C43/215—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring having unsaturation outside the six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C43/00—Ethers; Compounds having groups, groups or groups
    • C07C43/02—Ethers
    • C07C43/20—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring
    • C07C43/23—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring containing hydroxy or O-metal groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/04—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/08—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/58—One oxygen atom, e.g. butenolide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/70—Nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/70—Nitro radicals
    • C07D307/71—Nitro radicals attached in position 5
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/30—Hetero atoms other than halogen
    • C07D333/32—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/42—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms with nitro or nitroso radicals directly attached to ring carbon atoms
    • C07D333/44—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms with nitro or nitroso radicals directly attached to ring carbon atoms attached in position 5
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/54—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C07F7/1804—Compounds having Si-O-C linkages

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Furan Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Dichos compuestos, aunque están relacionados químicamente con la estructura de cis/trans-combretastatina, no siempre ligan a la tubulina, pero sin embargo presentan actividad citotóxica de interés en el campo oncológico como agentes anticáncer y/o antiangiogénicos. Reivindicación 1: Compuestos de fórmula (1) caracterizados porque: los diversos R1, R2, R3 y R4, que pueden ser iguales o diferentes, son H, OH, OPO3H2 u OCH2OPO3H2 y su sal disódica, OMe, OCH2O, NO2, F, Cl, Br; -R1-R2- también pueden ser juntos: -CR8=CR9-X-; Y es un radical seleccionado del grupo (2); R5 y R6, que pueden ser iguales o diferentes, son H o halógeno; R7 es H, OMe, SO2Ph; Ar es una estructura seleccionada del grupo (3); R8, R9 y R10, que pueden ser iguales o diferentes, son H, OH, OPO3H2 o OCH2OPO3H2 y su sal disódica, OR11, OCH2O, NH2, NHR11, NO2, alquilo C1-4, C6H5, C5H4N o halógeno; R11 es alquilo C1-4 o acilo, residuo de aminoácidos; X es O, S, N, NR12; R12 es H, CH3, CH2Ph; Z es CH, N; con la condición de que el compuesto de fórmula (1) no sea combretastatina A-1, combretastatin A-2, combretastatin A-4, y sus derivados fosfatos disódicos y con la exclusión de los siguientes compuestos: 2-fenil-6-trans-estiril-benzo[b]furano; 2,3-difenil- 6-trans-estiril-benzo[b]furano; 2-fenil-6-(4-metoxi)-trans-estiril-benzo[b]furano; 2-fenil-6-(3,4-dimetoxi)-trans-estiril-benzo[b]furano; 2-fenil-6-(3,4,5-trimetoxi)-trans-estiril-benzo[b]furano; 2-fenil-6-(3,4-metilendioxi)-trans-estiril- benzo[b]furano; 2,3-difenil-6-(4-metoxi)-trans-estiril-benzo[b]furano; 2-fenil-5-(3,4-metilendioxi)-trans-estiril-benzo[b]tiofeno; 2-fenil-6-trans-estiril-benzo[b]tiofeno; 2-fenil-6-(4-metoxi)-trans-estiril-benzo[b]tiofeno; 2-fenil-6-(4-cloro)-trans- estiril-benzo[b]tiofeno; Piceatanol; 1-(3-furanil)-2-(3,4,5-trimetoxifenil)eteno; 1-(3-tiofenil)-2-(3,4,5-trimetoxifenil)eteno; 1-(2-furanil)-2-(3,4,5-trimetoxifenil)eteno; y con la condición de que: - cuando R1 es hidrógeno y R2-R4 son 3,4,5- trimetoxi, Y es un doble enlace, R5 y R6 son H, Ar es fenilo, R8 y R9 son hidrógeno, R10 no es metoxi; - cuando R1 es hidrógeno y R2-R4 son 3,4,5-trimetoxi, Y es un doble enlace, R5 y R6 son H, Ar es fenilo, R8 es hidrógeno, R9 es 2-cloro, R10 no es 4-metoxi; - cuando R1 es hidrógeno y R2-R4 son trimetoxi, Y es un doble enlace, R5 y R6 son H, Ar es fenilo, por lo menos uno de R8-R10 no es hidrógeno; - cuando R1 es hidrógeno y R2-R4 son 3,4,5-trimetoxi, Y es un doble enlace, R5 y R6 son H, Ar es fenilo, R8 y R9 son hidrógeno, R10 no es ninguno de 4-cloro, 4-bromo, 4-nitro, 4-hidroxi, 4-acetilo, 4-etoxi, 4-alquilo C1-4; - cuando R1 es hidrógeno y R2-R4 son 3,4,5-trimetoxi, Y es un doble enlace, R5 y R6 son H, Ar es fenilo, R8 es hidrógeno, R9 es 4-nitro o 4-amino, R10 no es ninguno de 3-cloro, 3-metoxi, 3-metilo; - cuando R1 es hidrógeno y R2-R4 son 3,4,5-trimetoxi, Y es un doble enlace cis, R5 y R6 son H, Ar es fenilo, R8 es hidrógeno, R9 es 3-nitro o 3-amino, R10 no es ninguno de 3- cloro, 3-metoxi, 3-metilo; - cuando R1 es hidrógeno y R2-R4 son 2,3,4-trimetoxi, Y es un doble enlace, R5 y R6 son H, Ar es fenilo, R8 y R9 son hidrógeno, R10 no es 4-metoxi; - cuando R1 es hidrógeno y R2-R4 son 3,4,5-trimetoxi, Y es un doble enlace, R5 y R6 son H, Ar es fenilo, por lo menos uno de R8 es hidrógeno, R9 es 3-metoxi, R10 no es 5-metoxi; - cuando R1 es hidrógeno y R2-R4 son 3,4,5-trimetoxi, Y es un doble enlace, R5 y R6 son H, Ar es fenilo, R8-R10 no son metoxi; - cuando R1 y R2 son hidrógeno y R3-R4 son 3,4-dimetoxi, Y es un doble enlace, R5 y R6 son H, Ar es fenilo, R8 y R9 son hidrógeno, R10 no es 4-metoxi; - cuando R1 y R2 son hidrógeno y R3-R4 son 3,4-dimetoxi, Y es un doble enlace, R5 y R6 son H, Ar es fenilo, R8 es hidrógeno, R9-R10 no son 3,5-dimetoxi; - cuando R1 y R2 son hidrógeno y R3-R4 son 3, 4-dimetoxi, Y es un doble enlace, R5 y R6 son H, Ar es fenilo, por lo menos uno de R8-R10 no es hidrógeno; - cuando R1 y R2 son hidrógeno y R3-R4 son 3,5-metoxi, Y es un doble enlace, R5 y R6 son H, Ar es fenilo, R8 y R9 son hidrógeno, R10 no es 4-metoxi; - cuando R1 y R2 son hidrógeno y R3-R4 son 3,5-metoxi, Y es un doble enlace, R5 y R6 son H, Ar es fenilo, R8 y R9 son hidrógeno, Rio no es 4-acetilo; - cuando R1 es hidrógeno y R2-R4 son 3,4,5-trimetoxi, Y es un doble enlace, R5 y R6 son H, Ar no es piridilo; - cuando R1 es hidrógeno y R2-R4 son 3,4,5-trimetoxi, Y es un doble enlace cis, R5 y R6 son H, Ar es fenilo, R8 es hidrógeno, R9 es 3-amino, R10 es 4-NHR11, R11 no es el residuo de serina; - cuando R1 es hidrógeno y R2-R4 son 3,4,5-trimetoxi, Y es un doble enlace cis, R5 y R6 son H, Ar es fenilo, R8 es hidrógeno, R9 es 3-amino, R10 no es 4-metoxi; - cuando R1 es hidrógeno y R2-R4 son 3,4,5-trimetoxi, Y es un doble enlace cis, R5 y R6 son H, Ar es fenilo, R8 es hidrógeno, R9 es 3-amino, R10 no es un grupo 4-alquiloxi que tiene de 1 a 3 átomos de carbono, o un grupo 4-alquilo que tiene de 1 a 4 átomos de carbono, o un átomo de halógeno; - cuando R1 es hidrógeno y R2-R3 son 3,4-metilendioxi, R4 es 5-metoxi, Y es un doble enlace cis, R5 y R6 son H, Ar es fenilo, R8 es hidrógeno, R9 es 3-amino, R10 no es 4-metoxi; - cuando R1 es hidrógeno y R2-R4 son 2,3, 4-trimetoxi, Y es un doble enlace cis, R5 y R6 son H, Ar es fenilo, R8 es hidrógeno, R9 es 3-amino, R10 no es 4-metoxi;- cuando R1 es hidrógeno y R2-R4 son 3,4,5-trimetoxi, Y es un doble enlace cis, R5 y R6 son H, Ar es fenilo, R8 es hidrógeno, R9 es NHR11, R11 es el residuo de serina, R10 no es 4-metoxi; - cuando R1 es hidrógeno y R2-R3 son 3,4-metilendioxi, R4 es 4- metoxi, Y es un doble enlace cis, R5 y R6 son H, Ar es fenilo, R8 es hidrógeno, R9 es NHR11, R11 es el residuo del aminoácido cisteina, glicina, fenilalanina, serina, triptofano, tirosina, valina, R10 no es 4- metoxi; - cuando R1 es hidrógeno y R2-R3 son 3,4-metilendioxi, R4 es 4-metoxi, Y es un doble enlace, R5 y R6 son H, Ar es fenilo, R8 es hidrógeno, R9 es NO2 o NH2, R10 no es 4-metoxi; - cuando R1 es hidrógeno y R2-R4 son 3,4,5-trimetoxi, Y es un doble enlace cis, R5 y R6 son H, Ar es fenilo, por lo menos uno de R8-R10 no es hidrógeno;- cuando R1 es hidrógeno y R2-R4 son 3,4,5-trimetoxi, Y es un doble enlace, R5 y R6 son H, Ar es fenilo, R8 es hidrógeno, R9 es 4-metoxi, R10 no es 3-fluoro; - cuando R1 es hidrógeno y R2-R4 son 3,4,5-trimetoxi, Y es un doble enlace, R5 y R6 son H, Ar es fenilo, R8 es hidrógeno, R9 es 4-metilo, R10 no es 3-fluoro o 3-hidroxi; - cuando R1 es hidrógeno y R2-R4 son 3,4,5-trimetoxi, Y es un doble enlace cis, R5 y R6 son H, Ar es fenilo, R8 es hidrógeno, R9 es 4-metoxi, R10 no es 3-metoxi; - cuando R1 es hidrógeno y R2-R4 son 3,4,5-trimetoxi, Y es un doble enlace cis, R5 y R6 son H, Ar es fenilo, R8 es 3-fluoro, R9 es 4-metoxi, R10 no es 2- o 5-fluoro; - cuando R1 es hidrógeno y R2-R4 son 3,4,5-trimetoxi, Y es un doble enlace cis, R5 y R6 son H, Ar es fenilo, R8 es hidrógeno, R9 es 4-metoxi, R10 no es 3-hidroxi o 3-amino; - cuando R1 es hidrógeno y R2-R4 son 3,4,5-trimetoxi, Y es un doble enlace cis, R5 y R6 son H, Ar es fenilo, R8 es hidrógeno, R9 es 4-metoxi, R10 no es 3-fluoro o 3-bromo; - cuando R1 es hidrógeno y R2-R4 son 3,4,5-trimetoxi, Y es un doble enlace cis, R5 y R6 son H, Ar es fenilo, R8 y R9 son hidrógeno, R10 no es 4-hidroxi; - cuando R1 es hidrógeno y R2-R4 son 3,4,5-trimetoxi, Y es un doble enlace cis, R5 y R6 son H, Ar es fenilo, R8 es hidrógeno, R9 es 3-metilo, R10 no es 4-metilo;- cuando R1 es hidrógeno y R2-R4 son 3,4,5-trimetoxi, Y es un doble enlace cis, R5 y R6 son H, Ar es fenilo, R8 es hidrógeno, R9 es 4-metoxi, R10 no es 3-hidroxi;- cuando R1-R2 son hidrógeno y R3-R4 son 3,5-dihidroxi, Y es un doble enlace trans, R5 y R6 son H, Ar es fenilo, R8 es hidrógeno, R9 es 3-hidroxi, R10 no es 5-hidroxi; - cuando R1-R3 son hidrógeno, Y es un doble enlace, R5 y R6 son H, Ar es fenilo, R8 es hidrógeno, R9 y R10 son 3,4-dimetilo, y R4 no es 4-metoxi;- cuando R1-R2 son hidrógeno, Y es un doble enlace, R5 y R6 son H, Ar es fenilo, R8 es hidrógeno, R9 y R10 son 3,4-dimetilo, R4 es 4-metoxi,R3 no es 3-fluoro o 3-bromo o 3-nitro o 3-hidroxi; - cuando R1-R2 son hidrógeno, Y es un doble enlace, R5 y R6 son H, Ar es fenilo, R8-R10 son 3,4,5-trietoxi, R4 es 4-metoxi, R3 no es 3-fluoro o 3-cloro o 3-bromo o 3-hidroxi;- cuando R1-R2 son hidrógeno, R4 es 4-metoxi, Y es un doble enlace, R5 y R6 son H, Ar es fenilo, R8-R9 son 4,5-dimetoxi, R10 es 3-hidroxi, R3 no es 3-fluoro o 3- hidroxi; - cuando R1-R2 son hidrógeno, R4 es 4-metoxi, Y es un doble enlace, R5 y R6 son H, Ar es fenilo, R8-R9 son 4,5-dimetoxi, R10 es 3-metoxi, R3 no es 3-fluoro; - cuando R1 es hidrógeno, R2-R4 son 3,4,5-trimetoxi, Y es un doble enlace, R5 y R6 son H, Ar es 2-naftilo, por lo menos uno de R8-R10 no es hidrógeno; - cuando R1 y R2 son hidrógeno, R3 es 3-hidroxi, R4 es 4-metoxi, Y es un doble enlace, R5 y R6 son H, Ar es 2-naftilo, por lo menos uno de R8-R10 no es hidrógeno; - cuando R1 es hidrógeno, R2-R4 son 3,4,5-trimetoxi, Y es de fórmula (4), Ar es indolilo, en donde por lo menos uno de R8-R10 es diferente de hidrógeno; sus enantiómeros, diastereoisómeros, las mezclas respectivas y sus sales farmacéuticamente aceptables.
ARP040102518A 2003-07-18 2004-07-16 Derivados de combretastatina que presentan actividad citotoxica AR045700A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT000355A ITRM20030355A1 (it) 2003-07-18 2003-07-18 Composti ad attivita' citotossica derivati della combretastatina.

Publications (1)

Publication Number Publication Date
AR045700A1 true AR045700A1 (es) 2005-11-09

Family

ID=29765925

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP040102518A AR045700A1 (es) 2003-07-18 2004-07-16 Derivados de combretastatina que presentan actividad citotoxica

Country Status (13)

Country Link
US (1) US20060160773A1 (es)
EP (1) EP1646616A2 (es)
JP (1) JP2007530427A (es)
KR (1) KR20060039001A (es)
CN (1) CN1826330A (es)
AR (1) AR045700A1 (es)
AU (1) AU2004257011A1 (es)
BR (1) BRPI0412744A (es)
CA (1) CA2531389A1 (es)
IT (1) ITRM20030355A1 (es)
MX (1) MXPA06000625A (es)
TW (1) TW200504042A (es)
WO (1) WO2005007635A2 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ560712A (en) 2005-02-17 2010-12-24 Synta Pharmaceuticals Corp (3,4,5-trisubstituted-phenyl)isoxazole combretastin derivatives for the treatment of disorders
JP5149177B2 (ja) * 2005-07-25 2013-02-20 シンタ ファーマシューティカルズ コーポレーション 増殖性疾患の治療のための、チューブリンポリマー化の１，２，３−トリアゾール系抑制剤
US7781580B2 (en) * 2007-04-23 2010-08-24 Virginia Commonwealth University Stilbene derivatives as new cancer therapeutic agents
JP5302328B2 (ja) 2007-11-21 2013-10-02 オキシジーン， インコーポレイテッド 造血性新生物を治療するための方法
CN102026634B (zh) 2008-04-10 2014-01-22 弗吉尼亚州立邦联大学 诱导肿瘤缺氧以治疗癌症
CN102249987B (zh) * 2011-05-06 2013-07-24 兰州大学 一种考布他汀类化合物及其制备方法和用途
CN102863388B (zh) * 2011-07-05 2015-04-29 南京圣和药业股份有限公司 肿瘤靶向药物Combretastatin A4衍生物
WO2013047813A1 (ja) 2011-09-30 2013-04-04 大鵬薬品工業株式会社 １，２，４－トリアジン－６－カルボキサミド誘導体
PL220039B1 (pl) * 2012-03-29 2015-08-31 Univ Medyczny Im Karola Marcinkowskiego W Poznaniu Nowe pochodne (Z)-1,2-difenyloetenu
CN102993115B (zh) * 2012-12-08 2015-09-30 南京师范大学 一种3,5–二取代异噁唑啉衍生物及其合成方法和应用
JP2018523712A (ja) 2015-08-18 2018-08-23 マテオン セラピューティクス, インク.Mateon Therapeutics, Inc. 腫瘍に対する免疫調節療法を向上させる為のｖｄａｓの使用
US11434190B2 (en) * 2016-12-23 2022-09-06 The University Of Queensland Inhibitors of SOX18 protein activity for treating angiogenesis-and/or lymphangiogenesis-related diseases
JP2021500392A (ja) * 2017-10-25 2021-01-07 バイエル・ファルマ・アクティエンゲゼルシャフト ベンゾチオフェン−２−イルボロネートを調製するためのプロセス

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH540247A (de) * 1967-04-21 1973-09-28 Ciba Geigy Ag Verfahren zur Herstellung von heterocyclischen, Asthylendoppelbindungen enthaltenden Verbindungen
FR2558158B1 (fr) * 1984-01-13 1986-05-16 Roussel Uclaf Derives de l'indole ethenyl phenol, leurs sels, procede de preparation, application a titre de medicaments, compositions les renfermant et intermediaires
AU8641991A (en) * 1990-09-10 1992-03-30 Rhone-Poulenc Rorer International (Holdings) Inc. Substituted bicyclic aryl compounds exhibiting selective leukotriene b4 antagonist activity
GB9408577D0 (en) * 1994-04-29 1994-06-22 Fujisawa Pharmaceutical Co New compound
YU54202A (sh) * 2000-01-18 2006-01-16 Agouron Pharmaceuticals Inc. Jedinjenja indazola, farmaceutske smeše i postupci za stimulisanje i inhibiranje ćelijske proliferacije
US6897231B2 (en) * 2000-07-31 2005-05-24 Signal Pharmaceuticals, Inc. Indazole derivatives as JNK inhibitors and compositions and methods related thereto
WO2003087072A1 (en) * 2002-03-29 2003-10-23 Mochida Pharmaceutical Co., Ltd. Therapeutic agent for endothelial disorder

Also Published As

Publication number Publication date
WO2005007635A2 (en) 2005-01-27
CN1826330A (zh) 2006-08-30
WO2005007635A8 (en) 2005-05-12
BRPI0412744A (pt) 2006-09-26
JP2007530427A (ja) 2007-11-01
ITRM20030355A0 (it) 2003-07-18
AU2004257011A1 (en) 2005-01-27
EP1646616A2 (en) 2006-04-19
WO2005007635A3 (en) 2005-08-11
MXPA06000625A (es) 2006-04-19
CA2531389A1 (en) 2005-01-27
KR20060039001A (ko) 2006-05-04
US20060160773A1 (en) 2006-07-20
ITRM20030355A1 (it) 2005-01-19
TW200504042A (en) 2005-02-01

Similar Documents

Publication Publication Date Title
EA200300595A1 (ru) Соединения пиперазинилпиразинов в качестве антагонистов серотонин 5-ht2 рецептора
ES2183548T3 (es) Dihidropirimidinas.
DOP2015000014A (es) Derivados de azaadamantano y metodos de uso de los mismos
AR110056A2 (es) Modulación de receptores quimiosensoriales y ligandos relacionados con los mismos
ES2308299T3 (es) Tiadiazoles como ligandos de receptores de cxc-y cc-quimioquinas.
AR072969A1 (es) Derivados de ciclohexilamida, composiciones farmaceuticas y usos como antagonistas del receptor del factor de liberacion de corticotropina (crf - 1)
CO4900063A1 (es) Piridinas substituidas como inhibidores selectivos de ciclo- oxi-genasa2
MXPA03001186A (es) Compuestos heterociclicos como ligandos del receptor acido gamma aminobutirico (gabaa).
CR9459A (es) Derivados benzodioxano y benzodioxolano y usos de los mismos
CY1114932T1 (el) Αντιπαρασιτικοι παραγοντες
ECSP066447A (es) Derivados de isoquinolina 1,4-disustituida como inhibidores raf-quinasa útiles para el tratamiento de enfermedades proliferativas
CO5150159A1 (es) Derivados de 4-arilquinolin-2-ona 3-substituida como moduladores de los canales de potasio
AR032353A1 (es) Compuestos derivados biciclicos sustituidos para el tratamiento del crecimiento celular anormal y su uso en la fabricacion de medicamentos y composicion farmaceutica que los contiene
UY27503A1 (es) Nuevos derivados de piperazina
AR046926A1 (es) Combinaciones de inhibidor de erbb2 selectivo/anticuerpos anti-erbb en el tratamiento del cancer
PE20240022A1 (es) Derivados de fosforo como nuevos inhibidores de sos1
NO20052884L (no) Substituerte indolpyridinforbindelser som anti-infeksjonsmidler.
CY1108793T1 (el) Καμπτοθεκινες με τροποποιημενο λακτονικο δακτυλιο
UA117151C2 (uk) N-ациліміногетероциклічні сполуки
CY1114354T1 (el) Νεα παραγωγα βενζαμιδιου ως ανταγωνιστες βραδυκινινης
ATE282624T1 (de) Et-743 analoga als antitumoralverbindungen
AR065131A1 (es) Derivados triciclicos, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen
ECSP045420A (es) Derivados de benzoxazina como moduladores 5-ht6 y usos de los mismos
NO20061317L (no) Imidazopyridinderivater som induserbare NO-syntaseinhibatorer
EA200300988A1 (ru) Производные фенил-гетероциклильных эфиров в качестве ингибиторов обратного захвата серотонина

Legal Events

Date Code Title Description
FA Abandonment or withdrawal
FB Suspension of granting procedure